Evaluation of Anticancer Activity of 1,3-Oxazol-4-ylphosphonium Salts in Vitro.
1,3-Oxazol-4-yltriphenylphosphonium salts
Antiproliferation
Bioorganic chemistry
COMPARE correlations
Synthesis
Journal
ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013
Informations de publication
Date de publication:
19 Oct 2022
19 Oct 2022
Historique:
revised:
22
08
2022
received:
09
06
2022
pubmed:
30
8
2022
medline:
22
10
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
A novel series of 1,3-oxazol-4-yltriphenylphosphonium salts has been synthesized and functionalized. Oxazole derivatives were subjected to NCI in vitro assessment. Seven most active derivatives have been selected for five-dose assay. Among them, compounds 9 ([2-(4-methylphenyl)-5-[(4-methylphenyl)sulfanyl]-1,3-oxazol-4-yl]triphenylphosphonium perchlorate), 1 ([5-(4-methylphenyl)amino]-2-phenyl-1,3-oxazol-4-yl]triphenylphosphonium perchlorate) and 4 ([5-phenyl-2-[(4-methylphenyl)amino]-1,3-oxazol-4-yl]triphenylphosphonium perchlorate) were the most active against all tested cancer subpanels. Statistical analysis of the total panel data showed average values of parameters of anticancer activity in the range of 0.3-1.1 μM (GI
Identifiants
pubmed: 36037305
doi: 10.1002/cmdc.202200319
pmc: PMC9825890
doi:
Substances chimiques
Salts
0
Perchlorates
0
Antineoplastic Agents
0
Oxazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202200319Informations de copyright
© 2022 The Authors. ChemMedChem published by Wiley-VCH GmbH.
Références
Oncol Lett. 2017 Sep;14(3):3503-3509
pubmed: 28927105
Profiles Drug Subst Excip Relat Methodol. 2021;46:273-307
pubmed: 33461699
ChemistryOpen. 2012 Feb;1(1):33-8
pubmed: 24551490
Malawi Med J. 2012 Sep;24(3):69-71
pubmed: 23638278
Endocr Relat Cancer. 2013 May 21;20(3):371-81
pubmed: 23696597
J Biomol Struct Dyn. 2015;33(8):1653-68
pubmed: 25350567
Bioorg Med Chem. 2013 Jul 15;21(14):4170-7
pubmed: 23735826
J Physiol Pharmacol. 2017 Feb;68(1):13-26
pubmed: 28456766
Cancer Res. 1979 Dec;39(12):4868-74
pubmed: 227592
Int J Mol Sci. 2020 Aug 25;21(17):
pubmed: 32854415
Cancer Res. 1988 Aug 1;48(15):4423-6
pubmed: 3390838
Front Oncol. 2019 Aug 07;9:615
pubmed: 31440463
ChemMedChem. 2022 Oct 19;17(20):e202200319
pubmed: 36037305
Neoplasma. 1969;16(6):597-604
pubmed: 5369025
Eur J Biochem. 1973 Jun;35(2):251-8
pubmed: 4736920
Cell Biosci. 2020 Mar 10;10:31
pubmed: 32175074
Pharmacol Ther. 2019 Mar;195:111-131
pubmed: 30347213
Int J Mol Sci. 2020 Oct 26;21(21):
pubmed: 33114695
Biochim Biophys Acta Bioenerg. 2022 Feb 1;1863(2):148520
pubmed: 34896079
Oncology. 1982;39(4):242-9
pubmed: 7088474
Cancer Lett. 2019 Jan;440-441:23-34
pubmed: 30312728
Ther Drug Monit. 2017 Dec;39(6):584-588
pubmed: 29040228
Curr Pharm Biotechnol. 2020;21(15):1654-1665
pubmed: 32525770
Oncol Lett. 2018 Jun;15(6):8735-8743
pubmed: 29928324
Acta Pharm Sin B. 2018 Oct;8(6):862-880
pubmed: 30505656
Sci Rep. 2019 Oct 2;9(1):14171
pubmed: 31578425
Chem. 2020 Jun 11;6(6):1408-1419
pubmed: 32864504
Biochemistry (Mosc). 2013 Oct;78(10):1155-63
pubmed: 24237150
PLoS One. 2011;6(9):e23679
pubmed: 21935361
Anticancer Agents Med Chem. 2017;17(13):1796-1804
pubmed: 28730962
Cell Death Differ. 2016 Mar;23(3):369-79
pubmed: 26794443
Oncogene. 2001 Jul 12;20(31):4128-37
pubmed: 11464279
Clin Pharmacokinet. 2014 Aug;53(8):741-51
pubmed: 24968986
Biochem Pharmacol. 1966 Jun;15(6):763-8
pubmed: 5964255
Int J Nanomedicine. 2021 Jun 09;16:3907-3936
pubmed: 34135584
Int J Mol Sci. 2020 Sep 23;21(19):
pubmed: 32977472
Eur Endocrinol. 2018 Sep;14(2):62-66
pubmed: 30349596
J Pers Med. 2021 May 25;11(6):
pubmed: 34070567
Nat Rev Cancer. 2008 Jan;8(1):24-36
pubmed: 18097462
J Biol Chem. 1994 Nov 4;269(44):27322-8
pubmed: 7525553
Bioorg Med Chem Lett. 2009 Aug 15;19(16):4643-6
pubmed: 19615902
Cancer Res. 1987 Aug 15;47(16):4299-304
pubmed: 2440564
Cancer Res. 1977 Jul;37(7 Pt 1):2188-95
pubmed: 193637
Cancer Res. 2000 Mar 1;60(5):1229-35
pubmed: 10728681
Int J Med Sci. 2020 Oct 16;17(17):2831-2843
pubmed: 33162811